171 related articles for article (PubMed ID: 11754578)
1. Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase.
Debnath AK
J Med Chem; 2002 Jan; 45(1):41-53. PubMed ID: 11754578
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
3. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
da Cunha EF; de Castro Ramalho T; Bicca de Alencastro R; Maia ER
J Biomol Struct Dyn; 2004 Oct; 22(2):119-30. PubMed ID: 15317473
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional pharmacophore mapping of certain anticancer alpha-methylene-gamma-butyrolactones.
Lee KH; Huang BR
Oncol Res; 2003; 13(11):471-8. PubMed ID: 12812361
[TBL] [Abstract][Full Text] [Related]
5. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase.
Suling WJ; Reynolds RC; Barrow EW; Wilson LN; Piper JR; Barrow WW
J Antimicrob Chemother; 1998 Dec; 42(6):811-5. PubMed ID: 10052907
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
Rosowsky A; Cody V; Galitsky N; Fu H; Papoulis AT; Queener SF
J Med Chem; 1999 Nov; 42(23):4853-60. PubMed ID: 10579848
[TBL] [Abstract][Full Text] [Related]
7. A proposed model of Mycobacterium avium complex dihydrofolate reductase and its utility for drug design.
Kharkar PS; Kulkarni VM
Org Biomol Chem; 2003 Apr; 1(8):1315-22. PubMed ID: 12929661
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Rosowsky A; Fu H; Chan DC; Queener SF
J Med Chem; 2004 May; 47(10):2475-85. PubMed ID: 15115391
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.
Equbal T; Silakari O; Rambabu G; Ravikumar M
Bioorg Med Chem Lett; 2007 Mar; 17(6):1594-600. PubMed ID: 17236767
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim.
Rosowsky A; Forsch RA; Queener SF
J Med Chem; 2002 Jan; 45(1):233-41. PubMed ID: 11754594
[TBL] [Abstract][Full Text] [Related]
12. New antifolate inhibitors for Mycobacterium avium.
Barrow EW; Suling WJ; Seitz LE; Reynolds RC; Barrow WW
Med Chem; 2006 Sep; 2(5):505-10. PubMed ID: 17017990
[TBL] [Abstract][Full Text] [Related]
13. CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate reductase.
Gangjee A; Lin X
J Med Chem; 2005 Mar; 48(5):1448-69. PubMed ID: 15743188
[TBL] [Abstract][Full Text] [Related]
14. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
Rosowsky A; Forsch RA; Queener SF
J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
[TBL] [Abstract][Full Text] [Related]
15. A review of molecular modelling studies of dihydrofolate reductase inhibitors against opportunistic microorganisms and comprehensive evaluation of new models.
Tawari NR; Bag S; Degani MS
Curr Pharm Des; 2011; 17(7):712-51. PubMed ID: 21395543
[TBL] [Abstract][Full Text] [Related]
16. Binding mode analysis of 2,4-diamino-5-methyl-5-deaza-6-substituted pteridines with Mycobacterium tuberculosis and human dihydrofolate reductases.
da Cunha EF; Ramalho TC; Reynolds RC
J Biomol Struct Dyn; 2008 Feb; 25(4):377-85. PubMed ID: 18092832
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
Gangjee A; Lin X; Queener SF
J Med Chem; 2004 Jul; 47(14):3689-92. PubMed ID: 15214795
[TBL] [Abstract][Full Text] [Related]
18. A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors.
Adane L; Bharatam PV; Sharma V
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):635-45. PubMed ID: 19995305
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of human dihydrofolate reductase as a binary complex with the potent and selective inhibitor 2,4-diamino-6-{2'-O-(3-carboxypropyl)oxydibenz[b,f]-azepin-5-yl}methylpteridine reveals an unusual binding mode.
Cody V; Pace J; Nowak J
Acta Crystallogr D Biol Crystallogr; 2011 Oct; 67(Pt 10):875-80. PubMed ID: 21931219
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens.
Bag S; Tawari NR; Degani MS; Queener SF
Bioorg Med Chem; 2010 May; 18(9):3187-97. PubMed ID: 20363634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
